Psychiatria pre prax 4/2023
Why to prefer long-acting injectable antipsychotics of the second generation?
Soon after introducing antipsychotics (AP) in the fifties of the 20th century it was obvious that insufficient adherence will represent a major disadvantage of these oral drugs. This led to a development of the first long-acting injectable (LAI) drug in 1966 with the intention to reduce the occurrence of adverse events (AE) and to improve adherence at the same time.
Keywords: adverse events, adherence, long-acting injectable antipsychotics, oral antipsychotics, relaps
